RedCloud Bio is an innovative biotech company integrating experimental structural
pharmacology and computing technologies for the advancement of small molecule drug discovery and development. The Company has laboratories in Shanghai and Beijing.
RedCloud Bio has accumulated structural data covering targets of potential clinical value. With this foundation, RedCloud Bio has built its pipeline targeting tumor resistance as well as rare and other critical diseases with high unmet medical needs, using its core technology platform.
The Company’s lead therapeutic candidate, H002, is a small molecule compound addressing EGFR activating mutations. The compound is a next-generation TKI with unique clinical differentiation for non-small cell lung cancer and is expected to shortly enter global clinical development.
|
|
RedCloud Bio’s advanced structural pharmacology approach enables the Company to gain precise understanding of the detailed structure and mechanism of action for critical mutations, a crucial step for rational design and optimization of new drugs. We have integrated state-of-the-art screening algorithms and molecular dynamics/ computational chemistry-based compound optimization to facilitate discovery and optimization of new small molecule drugs with unprecedented specificity and efficiency.
Nanjing ｜307-311, Building No.9, 669-8 Xuanwu Avenue, Xuanwu District Shanghai｜Suite 901, 880 Xiangyang Road, Minhang District Beijing ｜Suite 205, Building No.2, PKUCare Industrial Park, Changping District Website: https://www.redcloudbio.com